Crucially, given the specific expression in regenerating cells and melanoma (and not in otherwise healthy tissues), PRL3 is a druggable target and a therapeutic antibody is in clinical trials for cancers with high levels of PRL3 (Chia et al., 2023; Thura et al., 2019). The gene discussed is PTP4A3; the disease is cancer.